Impact Capital Partners LLC Buys Shares of 1,775 Stryker Co. (NYSE:SYK)

Impact Capital Partners LLC bought a new stake in Stryker Co. (NYSE:SYK - Free Report) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 1,775 shares of the medical technology company's stock, valued at approximately $639,000.

A number of other hedge funds and other institutional investors have also modified their holdings of SYK. DecisionMap Wealth Management LLC acquired a new stake in shares of Stryker during the 4th quarter valued at about $280,000. HBK Sorce Advisory LLC raised its stake in shares of Stryker by 16.8% in the fourth quarter. HBK Sorce Advisory LLC now owns 807 shares of the medical technology company's stock valued at $291,000 after purchasing an additional 116 shares in the last quarter. Skandinaviska Enskilda Banken AB publ raised its stake in shares of Stryker by 61.7% in the fourth quarter. Skandinaviska Enskilda Banken AB publ now owns 165,820 shares of the medical technology company's stock valued at $60,070,000 after purchasing an additional 63,297 shares in the last quarter. Erste Asset Management GmbH raised its stake in Stryker by 7.7% during the fourth quarter. Erste Asset Management GmbH now owns 102,290 shares of the medical technology company's stock worth $37,602,000 after acquiring an additional 7,339 shares in the last quarter. Finally, Achmea Investment Management B.V. raised its stake in Stryker by 5.0% during the fourth quarter. Achmea Investment Management B.V. now owns 35,362 shares of the medical technology company's stock worth $12,733,000 after acquiring an additional 1,672 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

SYK has been the topic of several research analyst reports. JPMorgan Chase & Co. increased their target price on Stryker from $420.00 to $445.00 and gave the stock an "overweight" rating in a report on Wednesday, January 29th. Needham & Company LLC restated a "buy" rating and set a $442.00 target price on shares of Stryker in a report on Wednesday, January 29th. Canaccord Genuity Group raised their price target on Stryker from $420.00 to $435.00 and gave the company a "buy" rating in a report on Wednesday, January 29th. Morgan Stanley upgraded Stryker from an "equal weight" rating to an "overweight" rating and raised their price target for the company from $370.00 to $445.00 in a report on Monday, December 2nd. Finally, Stifel Nicolaus raised their target price on Stryker from $400.00 to $440.00 and gave the stock a "buy" rating in a report on Wednesday, January 29th. Five investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company's stock. According to MarketBeat, Stryker presently has a consensus rating of "Moderate Buy" and a consensus price target of $421.90.

Remove Ads

Insider Transactions at Stryker

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of the business's stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the transaction, the director now directly owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. The trade was a 5.24 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Allan C. Golston sold 2,458 shares of the business's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the completion of the transaction, the director now owns 14,895 shares of the company's stock, valued at $5,705,827.65. This represents a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 5.90% of the company's stock.

Stryker Price Performance

Shares of NYSE SYK opened at $363.52 on Thursday. Stryker Co. has a twelve month low of $314.93 and a twelve month high of $406.19. The firm has a market cap of $138.71 billion, a P/E ratio of 46.85, a PEG ratio of 2.93 and a beta of 0.95. The company has a 50 day moving average of $382.76 and a 200 day moving average of $373.33. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK - Get Free Report) last announced its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating analysts' consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter last year, the firm posted $3.46 earnings per share. As a group, research analysts expect that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a yield of 0.92%. The ex-dividend date of this dividend is Monday, March 31st. Stryker's payout ratio is 43.30%.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.